Safety and effectiveness of escitalopram in an 8-week open study in Chinese patients with depression and anxiety

References

• FerrariAJCharlsonFJNormanREBurden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010PLoS Med20131011e100154724223526
   PubMed Web of Science ®Google Scholar
• Global Burden of Disease Study 2013 CollaboratorsGlobal, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the global burden of disease study 2013Lancet2015386999574380026063472
   PubMed Web of Science ®Google Scholar
• LamRWDepression, Revised2nd edOxford University Press2012 Available from http://oxfordmedicine.com/view/10.1093/med/9780199692736.001.0001/med-9780199692736Accessed June 7, 2018
   Google Scholar
• GuptaSGorenADongPLiuDPrevalence, awareness, and burden of major depressive disorder in urban ChinaExpert Rev Pharmacoecon Outcomes Res201616339340726495800
   PubMed Web of Science ®Google Scholar
• GuLXieJLongJEpidemiology of major depressive disorder in mainland china: a systematic reviewPLoS One201386e6535623785419
   PubMed Web of Science ®Google Scholar
• BirnbaumHGKesslerRCKelleyDBen-HamadiRJoishVNGreenbergPEEmployer burden of mild, moderate, and severe major depressive disorder: mental health services utilization and costs, and work performanceDepress Anxiety2010271788919569060
   PubMed Web of Science ®Google Scholar
• HuTWHeYZhangMChenNEconomic costs of depression in ChinaSoc Psychiatry Psychiatr Epidemiol200742211011617235441
   PubMed Web of Science ®Google Scholar
• Evans-LackoSKnappMGlobal patterns of workplace productivity for people with depression: absenteeism and presenteeism costs across eight diverse countriesSoc Psychiatry Psychiatr Epidemiol201651111525153727667656
   PubMed Web of Science ®Google Scholar
• WuZFangYComorbidity of depressive and anxiety disorders: challenges in diagnosis and assessmentShanghai Arch Psychiatry201426422723125317009
   PubMedGoogle Scholar
• AdamsGCBalbuenaLMengXAsmundsonGJWhen social anxiety and depression go together: a population study of comorbidity and associated consequencesJ Affect Disord2016206485427466742
   PubMed Web of Science ®Google Scholar
• XinLMChenLJiZPRisk factors for anxiety in major depressive disorder patientsClin Psychopharmacol Neurosci201513326326826598584
   PubMed Web of Science ®Google Scholar
• ShiSSZhangMYWuWYMulti-center study of the clinical features in depression comorbidity with anxiety disordersShanghai Arch Psychiatry2009214198202
   Google Scholar
• deHeerEWGerritsMMBeekmanATThe association of depression and anxiety with pain: a study from NESDAPLoS One2014910e10690725330004
   PubMed Web of Science ®Google Scholar
• JiangKLiLWangXEfficacy and tolerability of escitalopram in treatment of major depressive disorder with anxiety symptoms: a 24-week, open-label, prospective study in Chinese populationNeuropsychiatr Dis Treat20171351552628255239
   PubMed Web of Science ®Google Scholar
• SaveanuREtkinADucheminAMThe international Study to predict optimized treatment in depression (iSPOT-D): outcomes from the acute phase of antidepressant treatmentJ Psychiatr Res20156111225586212
   PubMed Web of Science ®Google Scholar
• FavaMRushAJAlpertJEDifference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D reportAm J Psychiatry2008165334235118172020
   PubMed Web of Science ®Google Scholar
• PfeifferPNGanoczyDIlgenMZivinKValensteinMComorbid anxiety as a suicide risk factor among depressed veteransDepress Anxiety200926875275719544314
   PubMed Web of Science ®Google Scholar
• Guico-PabiaCJFayyadRSSoaresCNAssessing the relationship between functional impairment/recovery and depression severity: a pooled analysisInt Clin Psychopharmacol20122711721971533
   PubMed Web of Science ®Google Scholar
• GiliMGarcía ToroMArmengolSGarcía-CampayoJCastroARocaMFunctional impairment in patients with major depressive disorder and comorbid anxiety disorderCan J Psychiatry2013581267968624331287
   PubMed Web of Science ®Google Scholar
• PapakostasGIMajor depressive disorder: psychosocial impairment and key considerations in functional improvementAm J Manag Care20091511 SupplS316S32120088627
   PubMedGoogle Scholar
• GurejeOAdemolaAOlleyBODepression and disability: comparisons with common physical conditions in the Ibadan study of agingJ Am Geriatr Soc200856112033203818811605
   PubMed Web of Science ®Google Scholar
• NakanoYBabaHMaeshimaHExecutive dysfunction in medicated, remitted state of major depressionJ Affect Disord20081111465118304646
   PubMed Web of Science ®Google Scholar
• SheehanDVHarnett-SheehanKSpannMEThompsonHFPrakashAAssessing remission in major depressive disorder and generalized anxiety disorder clinical trials with the discan metric of the Sheehan disability scaleInt Clin Psychopharmacol2011262758321102344
   PubMed Web of Science ®Google Scholar
• ZimmermanMMcGlincheyJBPosternakMAFriedmanMAttiullahNBoerescuDHow should remission from depression be defined? The depressed patient’s perspectiveAm J Psychiatry2006163114815016390903
   PubMed Web of Science ®Google Scholar
• PintorLTorresXNavarroVMatraiSGastóCIs the type of remission after a major depressive episode an important risk factor to relapses in a 4-year follow up?J Affect Disord200482229129615488260
   PubMed Web of Science ®Google Scholar
• RomeraIPérezVCiudadAResidual symptoms and functioning in depression, does the type of residual symptom matter? A post-hoc analysisBMC Psychiatry2013135123398902
   PubMed Web of Science ®Google Scholar
• SheehanDVNakagomeKAsamiYPappadopulosEABoucherMRestoring function in major depressive disorder: a systematic reviewJ Affect Disord201721529931328364701
   PubMed Web of Science ®Google Scholar
• RushAJKraemerHCSackeimHAACNP Task ForceReport by the ACNP task force on response and remission in major depressive disorderNeuropsychopharmacology20063191841185316794566
   PubMed Web of Science ®Google Scholar
• SobockiPEkmanMAgrenHRunesonBJönssonBThe mission is remission: health economic consequences of achieving full remission with antidepressant treatment for depressionInt J Clin Pract200660779179816846399
   PubMed Web of Science ®Google Scholar
• CoplanJDAaronsonCJPanthangiVKimYTreating comorbid anxiety and depression: psychosocial and pharmacological approachesWorld J Psychiatry20155436637826740928
   PubMed Web of Science ®Google Scholar
• LepolaUMLoftHReinesEHEscitalopram (10–20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary careInt Clin Psychopharmacol200318421121712817155
   PubMed Web of Science ®Google Scholar
• BielskiRJVenturaDChangCCA double-blind comparison of escitalopram with venlafaxine extended release in the treatment of major depressive disorderJ Clin Psychiatry20046591190119615367045
   PubMed Web of Science ®Google Scholar
• KennedySHAndersenHFLamRWEfficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysisJ Psychiatry Neurosci200631212213116575428
   PubMed Web of Science ®Google Scholar
• KhooALZhouHJTengMNetwork meta-analysis and cost-effectiveness analysis of new generation antidepressantsCNS Drugs201529869571226293743
   PubMed Web of Science ®Google Scholar
• OliéJPTonnoirBMénardFGalinowskiAA prospective study of escitalopram in the treatment of major depressive episodes in the presence or absence of anxietyDepress Anxiety200724531832417041922
   PubMed Web of Science ®Google Scholar
• SheehanDVManciniMWangJAssessment of functional outcomes by Sheehan Disability Scale in patients with major depressive disorder treated with duloxetine versus selective serotonin reuptake inhibitorsHum Psychopharmacol2016311536326331440
   PubMed Web of Science ®Google Scholar
• WadeAGFernándezJLFrançoisCHansenKDanchenkoNDespiegelNEscitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost dataPharmacoeconomics2008261196998118850765
   PubMed Web of Science ®Google Scholar
• Association APDiagnostic and Statistical Manual of Mental Disorders (DSM)Washington, DCAmerican Psychiatric Association1994143147
   Google Scholar
• Sheehan Disability Scale (SDS) – Overview Available from: www.cqaimh.org/pdf/tool_lof_sds.pdfAccessed January 2, 2018
   Google Scholar
• EndicottJNeeJHarrisonWQuality of life enjoyment and satisfaction questionnaire: a new measurePsychopharmacol Bull19932923213268290681
   PubMed Web of Science ®Google Scholar
• GérardALiardFCrochardAGoniSMilletBDisability in patients consulting for anxiety or mood disorders in primary care: response to antidepressant treatmentNeuropsychiatr Dis Treat2012860561423271910
   PubMed Web of Science ®Google Scholar
• IsHakWWMirochaJPiSPatient-reported outcomes before and after treatment of major depressive disorderDialogues Clin Neurosci201416217118325152656
   PubMed Web of Science ®Google Scholar
• MontgomerySAAsbergMA new depression scale designed to be sensitive to changeBr J Psychiatry1979134382389444788
   PubMed Web of Science ®Google Scholar
• SajatovicMRamirezLFHamilton anxiety scale (HAM-A)Rating Scales in Mental Health3rd edBaltimore, USAThe John Hopkins University Press2012
   Google Scholar
• RushAJTrivediMHIbrahimHMThe 16-item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depressionBiol Psychiatry200354557358312946886
   PubMed Web of Science ®Google Scholar
• CohenJStatistical Power Analysis for the Behavioral Sciences2nd edNew York, NYAcademia Press1988
   Google Scholar
• DunlopBWLiTKornsteinSGCorrelation between patient and clinician assessments of depression severity in the PREVENT studyPsychiatry Res20101771–217718320304503
   PubMed Web of Science ®Google Scholar
• SheehanKHSheehanDVAssessing treatment effects in clinical trials with the discan metric of the Sheehan Disability ScaleInt Clin Psychopharmacol2008232708318301121
   PubMed Web of Science ®Google Scholar
• KaulVDuttaSBegMAComparative evaluation of amisulpride and escitalopram on Sheehan’s disability scale among depression patients in a tertiary care teaching hospital in NepalJ Drug Deliv Ther2015538
   Google Scholar
• MontgomerySAMansuyLRuthABoseALiHLiDEfficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled, proof-of-concept studyJ Clin Psychiatry201374436336923656841
   PubMed Web of Science ®Google Scholar
• BandelowBBaldwinDSDolbergOTAndersenHFSteinDJWhat is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder?J Clin Psychiatry20066791428143417017830
   PubMed Web of Science ®Google Scholar
• DemyttenaereKAndersenHFReinesEHImpact of escitalopram treatment on quality of life enjoyment and satisfaction questionnaire scores in major depressive disorder and generalized anxiety disorderInt Clin Psychopharmacol200823527628618703937
   PubMed Web of Science ®Google Scholar
• TrivediMHDunnerDLKornsteinSGPsychosocial outcomes in patients with recurrent major depressive disorder during 2 years of maintenance treatment with venlafaxine extended releaseJ Affect Disord2010126342042920510459
   PubMed Web of Science ®Google Scholar
• EndicottJLamRWHsuMAFayyadRBoucherMGuico-PabiaCJImprovements in quality of life with desvenlafaxine 50 mg/d vs placebo in employed adults with major depressive disorderJ Affect Disord201416630731425012446
   PubMed Web of Science ®Google Scholar
• FloreaIDanchenkoNBrignoneMLoftHRiveBAbetz-WebbLThe effect of vortioxetine on health-related quality of life in patients with major depressive disorderClin Ther201537102309232326346592
   PubMed Web of Science ®Google Scholar
• SheehanDVChokkaPRGrangerREWaltonRJRaskinJSagmanDClinical and functional outcomes in patients with major depressive disorder and painful physical symptoms switched to treatment with duloxetineHum Psychopharmacol201126324225121681815
   PubMed Web of Science ®Google Scholar
• SiTWangGYangFEfficacy and safety of escitalopram in treatment of severe depression in Chinese populationMetab Brain Dis201732389190128299626
   PubMed Web of Science ®Google Scholar
• HranovLGComorbid anxiety and depression: illumination of a controversyInt J Psychiatry Clin Pract200711317118924941356
   PubMed Web of Science ®Google Scholar
• PedersenAGEscitalopram and suicidality in adult depression and anxietyInt Clin Psychopharmacol200520313914315812263
   PubMed Web of Science ®Google Scholar
• GunnellDSaperiaJAshbyDSelective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA’s safety reviewBMJ2005330748838515718537
   PubMed Web of Science ®Google Scholar